
close report year end result vs estimate
adj ep vs estimate revenu
forecast co gross margin almost bp higher
estimate maintain buy rate share lower pt
adjust model reflect lower ebitda
estimate lower revenu estimate
ep forecast
ebitda estimate one main culprit estimate
reduct co decis make increas sales/market
invest investor like financi target
announc co share
think co strategi invest futur may pay road
largest competitor teva teva neutral aggress cut cost
even higher expect spend incur year
co expect gener enabl co
pay debt finish debt
put estim debt ebitda ratio base ebitda
estimate
posit expect recoveri co
american segment expect grow high-singl digit
year think may achiev co gener
advair launch along biosimilar includ fulphia
uptak biosimilar us slow past year think
could begin chang increas scrutini
high price brand biolog occur partner biocon
bio rate biosimilar includ lantu avastin
humira humalog enbrel last octob
launch hulio biosimilar rate humira
europ partner fujifilm kyowa kirin biolog
rate european market becom competit
switch biosimilar move rapidli within mani european countri
valuat arriv lower pt appli
multipl estim discount back
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
close report year end result vs estimate adj ep vs estimate
revenu forecast co gross margin almost bp higher estimate
maintain buy rate share lower pt adjust model
reflect lower ebitda estimate lower revenu estimate
ep forecast ebitda estimate one main
culprit estimate reduct co decis make increas sales/market invest
investor like financi target announc co share
think co strategi invest futur may pay road largest competitor teva
teva neutral aggress cut cost even higher expect spend incur
year co expect gener enabl co pay debt
finish debt put estim debt ebitda ratio base ebitda estimate
issu financi guidanc includ total revenu reflect
revenu attribut new product expect high-singl digit growth america mid-singl digit
growth europ rest world key financi metric includ ebitda
come consensu expect result higher sg invest also myl adj
tax rate expect increas
late januari fda approv myl gener version advair fluticasone/salmeterol treatment
asthma/copd estim brand market opportun us view approv gener
version advair import mileston co first-to-market opportun could still gener
signific revenu even though glaxosmithklin gsk rate advair sale declin
still meaning sale opportun brand sale still excess us
accord symphoni health advair high unit volum product total monthli prescript
estim gener advair sale could conserv figur
myl gener version advair wixela inhub includ three strength mcg mcg
mcg asthma patient sold discount brand counterpart advair disku
less gsk author gener version launch earlier month
recent announc wholesal acquisit cost mcg mcg
mcg wixela inhub also come strength mcg copd patient
believ dozen biosimilar product opportun includ top best-sel
biolog product believ could posit launch biosimilar version herceptin
trastuzumab brand market opportun us current partner biocon bio
rate biosimilar includ fulphila biosimilar rate neulasta
pegfilgrastim launch last year continu steadili gain share inject market
uptak biosimilar us slow past year think could begin chang
increas scrutini high price brand biolog occur
major biolog product target includ lantu avastin humira humalog
enbrel last octob launch hulio biosimilar rate humira europ
partner fujifilm kyowa kirin biolog rate european market becom
competit switch biosimilar move rapidli within mani european countri unlik us patent
major biolog expir includ enbrel remicad humira
partner biocon biosimilar includ lantu avastin humira
posit expect recoveri co american segment expect grow
high-singl digit year believ co biosimilar pipelin could drive growth especi
biosimilar version herceptin trastuzumab brand market opportun us launch
show myl expect growth across segment
arriv lower pt appli multipl estim
discount back view share remain inexpens even lower estim
share trade ev ebitda basi still teva closest compar
total net sale growth vs americahigh-singl digit new strateg product launch includ wixela inhub carryforward launch fulphila biosimilar neulasta yupelri continu uptak glatiram acet lower volum price exist product globaleuropemid-singl digit global includ dymista creon influvac betadin over-the-counter portfolio biosimilar includ hulio biosimilar humira ogivri biosimilar herceptin continu uptak glatiram acetaterest worldmid-singl digit expand reach china brazil continu focu australia japan biosimilar launchessourc co report segment net sale guidanc driversmylan discount cash discount discount valu multipl termin valu per co report btig estim
close report year end result vs estimate adj ep vs estimate
revenu forecast co gross margin almost bp higher estim
 incom statement north cost sg oper profit purchas account amort ad interest expens cash expens ep ep averag basic averag dilut analysissal co report btig estim
 incom statement financi project cost sg oper profit purchas account amort ad interest expens cash expens ep ep averag basic averag dilut co report btig
btig cover compani mention report
appendix analyst certif import disclosur
